EHA 2025 Congress

The European Hematology Association (EHA) 2025 Congress brings experts in hematology and oncology together to gain knowledge, collaborate, connect, and grow. The EHA 2025 Congress was held June 12–June 16, 2025 in Milan, Italy.

Dr. Gabriel Mannis Shares TUSCANY Trial Results of Tuspetinib Triplet in AML

Tuspetinib plus standard of care venetoclax and azacitidine in newly-diagnosed AML showed promising safety and efficacy.

$Treatment Innovations in Relapsed/Refractory CLL$

Treatment Innovations in Relapsed/Refractory CLL

Pirtobrutinib, CAR T, and bispecifics are reshaping CLL care for high-risk, relapsed patients with limited options.

CLL Trial Insights: Targeted Therapy Risks and Outcomes

BTK inhibitor safety: New analysis shows less hypertension risk with acalabrutinib or zanubrutinib vs ibrutinib in CLL.

Long-Term Outcomes and Innovations in Frontline ALL

Immunotherapy is reshaping ALL care, and short blinatumomab use may boost outcomes and reduce chemo-related toxicity.

Phase 3 Essential Thrombocythemia Trial: Novel Interferon-Based Agent Superior to Anagrelide

In the SURPASS ET trial, ropeginterferon alfa-2b was compared to anagrelide in second-line management of ET.

ALTITUDE-1: Real-World Elranatamab Patterns in Patients With Multiple Myeloma

A U.S. claims database study revealed how clinicians are administering elranatamab therapy in the real-world setting.

Dr. Susan O’Brien Shares ‘Encouraging’ SEQUOIA Trial Data in CLL

Dr. O’Brien described the safety and efficacy of zanubrutinib and the benefits of combining the drug with other agents.

$Novel Combination Exceeds Standard Therapy for Relapsed or Refractory Multiple Myeloma$

Novel Combination Exceeds Standard Therapy for Relapsed or Refractory Multiple Myeloma

Talquetamab plus teclistamab yields high responses in patients with relapsed/refractory myeloma and extramedullary disease.

Novel Calreticulin-Mutation-Targeting Antibody Safe, Effective for High-Risk ET

Dose escalation study data presented at EHA2025 showed durable response in patients with disease resistant to prior therapy.

New Era in Cell Therapy: Insights on Locabtogene Autoleucel

Dr. Susan Bal unpacks the promise of GPRC5D CAR T therapy in relapsed/refractory multiple myeloma.

Subcutaneous Mosunetuzumab Induced High Response Rates in First-Line MZL

Mosun SC shows positive ORR and CMR rates in first-line MZL, offering an effective, outpatient-friendly treatment option.

KOMET-001 Trial Reveals Emerging Option for Mutant Acute Myeloid Leukemia

Ziftomenib shows strong, lasting responses in R/R NPM1-mutant AML, according to KOMET-001 data shared at EHA 2025.

ZUMA-3 Underscores Durable Survival Gains with Brexu-Cel in Relapsed B-Cell ALL

Brexu-cel shows a significant 5-year OS rate in R/R B-ALL patients, with survival benefits across key subgroups in ZUMA-3.

Elotuzumab Boosts KRd Regimen in Newly Diagnosed Multiple Myeloma, Study Finds

Elotuzumab added to KRd shows a favorable trend in 3-year PFS for NDMM patients, EHA 2025 study finds.

Talquetamab Still Works Well in Myeloma Patients, Even With Immune Response

Talquetamab remains effective in tough-to-treat myeloma—even when patients develop immune responses.

Early Data Suggest DNA Damage Boost in R/R AML with Talazoparib Plus GO

Talazoparib plus GO shows early signs of activity in relapsed/refractory AML, warranting further study, per EHA 2025 poster.

EHA 2025 Congress

EHA 2025 unites global hematology experts to learn, connect & advance care—June 12–16 in Milan, Italy.

$Sonrotoclax Plus Zanubrutinib Yields High Response Rates in Relapsed/Refractory MCL$

Sonrotoclax Plus Zanubrutinib Yields High Response Rates in Relapsed/Refractory MCL

Sonrotoclax plus zanubrutinib shows promising efficacy and safety in relapsed/refractory MCL, per EHA 2025 data.

Phase 3 IMROZ Trial Spotlights Isa-VRd Survival Benefit for Patients With Newly Diagnosed Myeloma

Isatuximab added to bortezomib, lenalidomide, and dexamethasone showed a significant PFS benefit in myeloma.